Gunilla Lundmark new board member of CombiGene
At CombiGene’s Annual General Meeting, Gunilla Lundmark was elected as new member of the Board of Directors. Gunilla is an entrepreneur through and through, and has 25 years of experience from leading positions in the life science industry. Gunilla’s successful entrepreneurship was manifested in 2014 in the “2014 BioTech Builder Prize”. Gunilla is the CEO of Uppsala University Invest AB since 2018 and has previously held a number of leading positions at companies such as Pharmanest AB and Q-Med AB.
“Gunilla’s long experience in the life science industry and her stated entrepreneurial skills will mean a lot to the continued development of CombiGene,” CombiGene Chairman Bert Junno comments.
“I am very much looking forward to being part of CombiGene’s Board of Directors. I’m impressed with the company’s work so far. CombiGene has a very exciting and promising time ahead of it, not least in the epilepsy project that is approaching the first study in humans,” says Gunilla Lundmark.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.